It’s only fair to share… Revumenib FDA APPROVED 11/15/2024, Revuforj, To treat relapsed or refractory acute leukemia N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide Ingredient UNII CAS InChI Key Revumenib citrate YL4RYN734D 2761046-45-9 UBXFWTFPYATLBT-SGBGZXBGSA-N Revumenib sesquifumarate 75HI05N8HS 2169919-22-4 AXNUWYROYVRYIM-OQIJCFCCSA-N Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements.[1] It is designed to disrupt the …